Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
about
Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis preventionModern Radiotherapy Concepts and the Impact of Radiation on Immune ActivationPrognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysisImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsRelevance of tumor-infiltrating lymphocytes in breast cancerImmunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectivesHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerTumor immunotherapy: lessons from autoimmunityAntitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentationNeo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting.Shaping the repertoire of tumor-infiltrating effector and regulatory T cells.Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expressionTug-of-war between driver and passenger mutations in cancer and other adaptive processesOligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.Anti-p21 autoantibodies detected in colorectal cancer patients: A proof of concept study.Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent.Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8Trial Watch: Therapeutic vaccines in metastatic renal cell carcinomaIn Vivo Suppression of Heat Shock Protein (HSP)27 and HSP70 Accelerates DMBA-Induced Skin Carcinogenesis by Inducing Antigenic Unresponsiveness to the Initiating Carcinogenic Chemical.Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.Combined fibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer.Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo.Targeting neoantigens for cancer immunotherapyInhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?Metabolic control of tumour progression and antitumour immunityImmunoregulatory activity of adenosine and its role in human cancer progression.Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.Therapeutic vaccines for cancer: an overview of clinical trials.The potential role of immunotherapy to treat colorectal cancer.Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.Antigen processing and immune regulation in the response to tumours.Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.T Cell Genesis: In Vitro Veritas Est?mRNA Cancer Vaccines.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
P2860
Q21195742-BD95BF45-1A90-4F3F-82D3-A9A88B28AF40Q26744490-0B2BD0D7-1162-49BA-B811-6C2F57C7E7CDQ26773406-20142F51-1F1B-4FB9-B426-36AB813B6BD3Q26781538-B0E87FF9-D499-44C1-B415-717F388C5A84Q26795598-640741A6-8A4A-41A1-B5DB-2C9DA18F4596Q26849530-5E36F046-0020-4972-A26F-DC7071E07ECDQ26863418-28ECA6D1-EA69-4042-BD3D-1CF238F06EA9Q26866179-62406C7B-F675-4F35-B763-D070C2145ADAQ27026193-D66CFEC6-C5F4-4869-9E59-0646DEC33F60Q33564510-D1187040-7935-4E26-88CE-BDBDEEA78B28Q33736218-22BC171A-8772-4DB8-AB34-32E77DF223C0Q33891641-C274E1F2-3CAA-47B0-9E1D-BC2ED4B249E9Q34003592-A50B630F-C5AB-4316-935A-441789269FD0Q34240499-EE531ADC-3F10-4E57-8E6A-CA674063871BQ34409055-FD9621B1-EA03-4531-BE65-FF9D80C8F93DQ34748629-1E27152B-DF0F-4599-A36F-BD5291B9E872Q35149457-C784247D-06AB-4CFA-9B9A-A9E2E535E96FQ35201847-C7363514-B83E-4988-B23C-7D41B074AD3AQ35663861-88C56D7A-CF3F-434F-91BB-7D37765F5735Q35724710-DEF1FB07-3B6D-4014-B7BE-58F2597C2515Q35799377-5363F4E6-A8AB-4955-997E-2530B5657BC1Q36288880-FC10C117-2C55-46C5-ABE5-86DC87D3A819Q36322760-87A15FAC-A4F7-4FCC-A7DC-4E44B3462D20Q36524772-70A3EDBB-D572-4F13-999D-A2130874B647Q37032948-6B803D3A-C532-46A7-889B-1682521C102BQ37223669-1424C54A-1212-48E0-82F9-1B7F901AF677Q37697529-BF170554-221B-4A7C-B308-185BD4DDF8DBQ38151562-7D5DF43E-51EF-43FA-9F9A-0FF6AE376420Q38168678-9F871085-95CC-4213-B80F-89687E30DBFFQ38215678-29EDFDFC-5B7E-4ACF-9466-C34EA14B5A66Q38217593-0B6CBF0A-1DE6-49D6-BBF3-A0B8CFCF1950Q38218786-0DF42761-F7E0-4964-8DD5-AE14CC58B02BQ38227030-DE5FFB7D-28E5-4F9E-8C54-DEAB0BCDC0F1Q38292169-0D46AF01-D5F8-4D46-944A-2CEBDBA07779Q38734804-259C9FBE-902F-477A-B9B2-5827C5607179Q38818628-EA015AD0-F57A-4F5A-96BC-1D11710322DFQ38924557-BE80B968-EEA9-4468-9D5C-B365324A7865Q38992976-30BCFDD8-430D-43D9-8517-AAFAFE18943AQ39013357-B06D506F-DB3D-4CA4-864B-F908164E24D9Q39013616-48DA9664-2DCF-47B1-9EFD-5F0F95BB18A1
P2860
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
@en
type
label
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
@en
prefLabel
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
@en
P2860
P356
P1476
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
@en
P2093
Matthew D Vesely
Robert D Schreiber
P2860
P356
10.1111/NYAS.12105
P407
P577
2013-05-01T00:00:00Z